Fellow's quick read · Infectious Diseases
Vaccination of the immunocompromised host
IDSA 2013 (Rubin et al) + IDSA 2025 focused update (COVID / influenza / RSV) · reviewed 2026-07-15
Personal study digest for a new ID fellow. Recommendations are drawn from the 2013 IDSA guideline (Rubin et al, Clin Infect Dis 2014) and the 2025 IDSA rapid update on COVID-19, influenza, and RSV in immunocompromised patients (Clin Infect Dis 2025/2026). The “What’s changed since 2013” section is reviewer synthesis of newer evidence, each claim cited. Federal (ACIP/CDC) schedule specifics are in flux for 2025–2026 — confirm the exact schedule against current CDC before acting. Not a substitute for the full guideline.
In one line
Two rules carry the field: vaccinate BEFORE immunosuppression (inactivated ≥2 weeks before, live ≥4 weeks before), and once highly immunosuppressed, give NO live vaccines. The modern twist — the non-live recombinant/subunit replacements (RZV/Shingrix for zoster; the RSV vaccines) are now recommended for the immunocompromised. And vaccinate every household contact — their immunity is the patient’s shield.◆Who this covers & the core split
- “Immunocompromised” (2025 definition): hematologic malignancy, primary immunodeficiency, autoimmune disease on immunosuppressants/biologics, HIV with severe immunosuppression (CD4 <15% or <200/mm³), and recipients of solid organ transplant (SOT), hematopoietic cell transplant (HCT), CAR-T, or solid-tumor chemotherapy.
- The whole guideline runs on one axis: inactivated vaccines (killed / subunit / conjugate / mRNA) are always safe — the only question is whether the patient will respond. Live vaccines are the danger — the question is whether they’re allowed at all.
- Degree matters: some live vaccines are acceptable under low-level immunosuppression but are off the table once highly immunosuppressed.
◆The timing rules (memorize these)
- Vaccinate before planned immunosuppression whenever feasible (strong, moderate) — this is the single best, sometimes only, window for live vaccines.
- Live vaccines: ≥4 weeks before immunosuppression; never within 2 weeks of starting (strong, low).
- Inactivated vaccines: ≥2 weeks before immunosuppression (strong, moderate).
- Anti–B-cell therapy (e.g., rituximab): responses are near-zero — delay live vaccines ≥6 months after the regimen (Rec 73); the influenza dose is expected to fail if given within 6 months of anti–B-cell antibody.
- Vaccines given during chemotherapy don’t count as valid doses unless a protective antibody level is documented (Rec 71).
◆Core vaccines — what to give the IC patient
| Vaccine | Give to the IC patient? | Timing / caveat |
|---|---|---|
| Influenza (inactivated, IIV) | Yes — annual, all IC ≥6 mo | High-dose/adjuvanted may help; LAIV (live) contraindicated. Skip only if won’t respond (intensive chemo, anti–B-cell <6 mo) |
| COVID-19 | Yes — age-appropriate (strong, 2025) | Moderately/severely IC get ≥1 extra dose vs general population; time ~2 wk pre- or ≥3 mo post-immunosuppression |
| RSV | Yes — adults/adolescents (strong, 2025) | Non-live (RSVPreF3, RSVPreF, mRNA-1345); <18 y = shared decision-making |
| Pneumococcal (PCV) | Yes | Current: single PCV20 or PCV21 (updated from the 2013 PCV13→PPSV23 step — see below) |
| Recombinant zoster (RZV / Shingrix) | Yes — 2 doses, IC ≥19 | Non-live; replaces live Zostavax (see below) |
| Live: MMR / varicella / LAIV / MMRV | No if highly IC | Give only ≥4 wk BEFORE immunosuppression, or in defined post-recovery windows (see special populations) |
◆Household contacts (the cocoon)
- Contacts ≥6 mo: annual influenza — IIV preferred; LAIV is acceptable if the contact is healthy, non-pregnant, aged 2–49, except avoid LAIV around a patient who is <2 mo post-HSCT, has GVHD, or has SCID (or avoid contact for 7 days).
- Contacts can receive MMR, varicella, zoster, rotavirus, yellow fever, and oral typhoid. Do NOT give OPV to a household contact.
- Precautions: if a contact develops a rash after varicella/zoster vaccine, the patient avoids them until lesions clear; a highly IC patient avoids handling diapers of a rotavirus-vaccinated infant for 4 weeks.
◆Special populations
- HSCT — the big one: transplant erases prior immunity, so re-immunize from scratch. Inactivated series restart ~6 months post-HSCT (PCV series from 3–6 mo; influenza from 6 mo, or 4 mo in an outbreak). Live MMR/VAR delayed to 24 months post-HSCT — and only if no GVHD and no ongoing immunosuppression.
- SOT: vaccinate pre-transplant (best window). After SOT, hold during the first ~2 months / intensified immunosuppression; resume inactivated 2–6 mo post. Live MMR/VAR generally NOT given post-SOT. Never withhold a needed vaccine for fear of rejection.
- HIV: inactivated vaccines per schedule; live vaccines gated by CD4 — MMR and varicella only if CD4 ≥200 (children ≥15%) and no severe immunosuppression; no LAIV, no MMRV.
- Asplenia / sickle cell: the encapsulated-organism bundle — pneumococcal, meningococcal (ACWY + B), and Hib. For elective splenectomy, vaccinate ≥2 weeks before surgery; meningococcal boosters every 5 years.
◆Key decisions a fellow owns
- Time it: get vaccines in before immunosuppression starts (live ≥4 wk, inactivated ≥2 wk).
- Pick the non-live option when one exists: RZV not Zostavax; IIV not LAIV; the recombinant/mRNA/subunit RSV and COVID vaccines are all non-live and fair game.
- After rituximab / anti–B-cell: wait — delay live vaccines ≥6 months and expect blunted inactivated responses.
- Vaccinate the household to cocoon the patient (flu for all; MMR/VAR/rotavirus are safe for contacts; never OPV).
- Don’t miss the pre-transplant window — it is often the only chance for live vaccines in SOT/HSCT candidates.
- Confirm the current CDC/ACIP schedule — pneumococcal, RSV age, and COVID dosing all changed after 2013 and remain in flux for 2025–2026.
What’s changed since 2013
Reviewer synthesis — not the guideline. Deep currency check; each item cited.
- Zoster: live → recombinant, a full reversal for the IC host. The 2013 guideline knew only the LIVE zoster vaccine (Zostavax) and said don’t give it to the highly immunocompromised. Zostavax was withdrawn from the US market (18 Nov 2020). The non-live recombinant RZV (Shingrix) is now the only US zoster vaccine and is recommended FOR immunocompromised adults ≥19 (2-dose series) — ACIP Oct 2021 (Anderson, MMWR 2022;71:80–84; PMID 35051134). Efficacy 68.2% in autologous HSCT (ZOE-HSCT, Bastidas, JAMA 2019;322:123–133; PMID 31287523).
- Pneumococcal: the PCV13→PPSV23 two-step is gone. For IC adults ≥19, a single dose of PCV20 or PCV21 (no following PPSV23), or PCV15→PPSV23, replaces the 2013 sequence; routine PCV age lowered to ≥50 (ACIP 2024; MMWR 2024;73:mm7336a3 & MMWR 2025;74:mm7401a1).
- RSV: brand-new category, strongly recommended. Three non-live adult RSV vaccines (RSVPreF3/Arexvy, RSVPreF/Abrysvo, mRNA-1345/mResvia). 2025 IDSA IC update: strong rec — RSV vaccine cut RSV-associated hospitalization ~70% (95% CI 66–73%) in IC adults; Guillain-Barré ~11 excess cases/million doses (Tan, Clin Infect Dis 2025; PMID 41766598; DOI 10.1093/cid/ciag117).
- COVID-19: new since 2013, strong rec. 33–56% reduction in hospitalization in IC; moderately/severely IC get ≥1 additional dose vs the general population (Nellore, Clin Infect Dis 2025; PMID 41739597; DOI 10.1093/cid/ciag115).
- Influenza: confirmed and refined. The 2025 update reaffirms annual inactivated flu for all IC (32% fewer flu hospitalizations) and adds that high-dose or adjuvanted formulations may improve response; LAIV still contraindicated (Goepfert, Clin Infect Dis 2025; PMID 41762115; DOI 10.1093/cid/ciag116).
- Who issued the 2025 rec (recency-sensitive context). IDSA developed the 2025 COVID/flu/RSV-in-IC guideline via the independent Vaccine Integrity Project (CIDRAP / University of Minnesota, led by M. Osterholm) amid disruption to the federal ACIP/CDC advisory process in 2025. Treat federal schedule specifics as in flux (IDSA umbrella: Nellore, Clin Infect Dis 2025; PMID 41766454; DOI 10.1093/cid/ciag114; VIP evidence review: Scott J et al, N Engl J Med 2025;393:2221–42).
- Still current: the timing rules (live ≥4 wk / inactivated ≥2 wk before immunosuppression), no-live-vaccines-when-highly-IC, HSCT full re-immunization from ~6 months, live vaccines gated by CD4 in HIV, and the household-cocoon strategy all remain the backbone.
◆Anki cards minted this run
Added to Bugs and Drugs Clinicals (model Basic-6610e), dedup-checked against the deck. Tags on each: Guideline::IDSA::IC_Vaccines + Subject::Infectious_Disease. (Anki was briefly offline mid-run; a backup TSV IC_Vaccines_2026-07-15_anki-cards.tsv was also written.)
- Zoster reversal — recombinant RZV/Shingrix (non-live), 2 doses, now recommended for IC ≥19; replaces contraindicated live Zostavax (ZOE-HSCT 68%).
- Pneumococcal update — IC adult ≥19: single PCV20 or PCV21 (no PPSV23), replacing PCV13→PPSV23.
- Live vaccines after HSCT — MMR/varicella wait ≥24 months post-HSCT, and only if no GVHD / ongoing immunosuppression.
- RSV in the IC host — 2025 IDSA strong rec; non-live RSV vaccine cut RSV hospitalization ~70% in IC adults.
Sources:
(1) Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 2014;58(3):e44–e100. DOI 10.1093/cid/cit684.
(2) Nellore A, Goepfert P, Tan CS, et al. IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, influenza, and RSV infections in immunocompromised patients. Clin Infect Dis 2025. PMID 41766454; DOI 10.1093/cid/ciag114.
(3) Nellore A, et al. IDSA 2025 — COVID-19 in immunocompromised patients. PMID 41739597; DOI 10.1093/cid/ciag115.
(4) Goepfert P, et al. IDSA 2025 — influenza in immunocompromised patients. PMID 41762115; DOI 10.1093/cid/ciag116.
(5) Tan CS, et al. IDSA 2025 — RSV in immunocompromised patients. PMID 41766598; DOI 10.1093/cid/ciag117.
(6) Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: ACIP — United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71(3):80–84. PMID 35051134; DOI 10.15585/mmwr.mm7103a2.
(7) Bastidas A, de la Serna J, El Idrissi M, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation (ZOE-HSCT): A Randomized Clinical Trial. JAMA 2019;322(2):123–133. PMID 31287523; DOI 10.1001/jama.2019.9053.
(8) Kobayashi M, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: ACIP — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73(36). And Expanded Recommendations for PCV Use Among Adults Aged ≥50 Years: ACIP 2024. MMWR 2025;74(1).
(9) Scott J, Abers MS, Marwah HK, et al. Updated evidence for COVID-19, RSV, and influenza vaccines for 2025–2026. N Engl J Med 2025;393(22):2221–2242 (Vaccine Integrity Project evidence review).
Currency layer verified via PubMed and CDC/ACIP MMWR; DOIs resolved from PubMed. Reviewer synthesis is clearly separated from guideline text.